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1. Introduction 
A new group of biologically active compounds, the 
leukotrienes, has been described in [l-4]. These 
derivatives of arachidonic acid and other polyunsatu- 
rated fatty acids are formed by initial oxygenation at 
C-5 forming 5hydroperoxy acids. The hydroperoxy 
derivative is further converted to a labile allylic epox- 
ide intermediate leukotriene Aa (LT&) (from arachi- 
donic acid) [5,6]. LT& can be converted to LTB4 
[7,8] by enzymatic hydrolysis [9], and to LTC4 
[ 10-121, by addition of glutathione [ 131. LTC4 
together with the metabolites LTD4 [ 141 and LTE4 
[ 15,161 are the structures responsible for the biologi- 
cal activity referred to as SRS-A in [ 171. Here, and in 
[ 181, we report that leukotriene formation is not 
restricted to transformations involving oxygenation at 
C-5 as the first step. A new group of leukotrienes can 
also be formed in biological systems by initial oxygen- 
ation at C-l 5. 
2. Materials and methods 
2.1. Materials 
Dextran T-500 for cell sedimentation was obtained 
from Pharmacia Fine Chemicals (Uppsala). Arachi- 
Abbreviations: LT, ieukotriene; LTA,, leukotriene A., (5(S)- 
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tetraenoic acid); LTC,, leukotriene C, (S(g)-hydroxy,6(R)S- 
glutathionyl-7,9-trans,11,14-cis-eicosatetraenoic acid;LTD,, 
leukotriene D, (S(S)-hydroxyd(R)S-cysteinylglycyl-7,9- 
irans,l1,14cis-eicosatetraenoic acid; LTE,, leukotriene E, 
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Fig.1. Transformations of arachidonic acid in human leuko- 
cytes via initial oxygenation at C-15. Structure in brackets is 
postulated. Asterisk indicates that the stereochemistry of the 
conjugated triene has not been determined. 
donic acid was purchased from Nu-Chek Prep. (Elysian 
MN) and soybean lipoxygenase (EC 1 .13 .l 1 .12) 
type I, from Sigma (St Louis MO). HPLCequipment 
was from Waters Assoc. (Milford MA) (pump 6000A, 
injector U6K) and LDC (Riviera Beach FA) (UV-de- 
tector, LDC-III), respectively. HPLC stationary phases 
were from Macherey-Nagel, (Diiren). 
2 2. Preparation of human leukocytes 
A concentrate of human leukocytes was obtained 
from blood component preparation at the Karolinska 
Hospital. The cells were preparated as in [21]. Briefly, 
the cell suspension was mixed with an equal volume 
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of 6% (w/v) Dextran T-500 in 0.9% saline, and the 
cells were allowed to sediment at 4°C. This separated 
the majority of the red cells from the white cells. 
After centrifugation at 400 X g 15 min, the pellets 
were resuspended in a Tris-buffered, ammonium- 
chloride solution, and incubated at 37°C for 7 min, 
to induce lysis of remaining red cells. Succeeding cen- 
trifugation at 400 X g for 15 min, the cells were resus- 
pended in Dulbeccos PBS, 30 X 106/ml, for immedi- 
ate incubation. 
2.3. Preparation of IS-hydroperoxyeicosatetraenoic 
acid (15-HPETE) 
IS-HPETE was produced by incubation of soybean 
Bpoxygenase with arachidonic acid [ 191. The product 
was extracted with diethylether, after acidification 
@H 2.5). It was purified by silicic acid column chro- 
matography (CC4, Mallinkrodt, St Louis MO), acti- 
vated overnight at 12O’C. The sample was applied to 
the column dissolved in diethylether/hexane (90110, 
v/v) and eluted with diethylether/hexane (80/20, v/v). 
The purified material was stored in methylene chlo- 
ride at -20°C. The identity and purity of the product 
was determined by cochromatography with 15-hy- 
droxyeicosatetraenoic acid on straight phase HPLC, 
after reduction with triphenylphosphine. 
2.4. Incubations 
The human leukocyte preparation (30 X 106/ml), 
was pre-warmed to 37°C. I5-HPETE dissolved in 
ethanol was added to 80 PM final cont. and incubated 
for 30 min. The amount of ethanol never exceeded 
0 .I % of the incubation volume. Typically 100 ml cell 
suspension was used. The incubations were stopped 
by adding 1.5 vol. methanol. 
2 5. Extraction and punfication procedure 
The precipitate obtained upon addition of metha- 
nol to the incubation was spun down, and washed 
once with methanol. The aqueous phase was acidified 
with hydrochloric acid to pH 2-3, and extracted with 
diethylether . 
After evaporation, the extract was applied to a 
silicic acid column (CC4, Mallinkrodt , St Louis MO) 
2 g/50 ml incubation vol. The column was eluted with 
hexane/diethylether (90/10, v/v) followed by ethyl- 
acetate. The ethylacete fraction was evaporated and 
further purified on a semi-preparative reverse phase 
HPLCcolumn (Polygosil Cl 8, 10 pm particles, length 
500 mm, i.d. 10 mm) that was eluted with methanol/ 
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water/acetic acid (70/30/0.01, v/v/v) at 4 ml/min. 
UV-absorption at 280 nm of the eluate was moni- 
tored. Fractions showing a leukotriene-type UVspec- 
trum were pooled and methylated with diazomethane. 
Final purification was achieved on a straight phase 
HPLCcolumn (Polygosil C60-10, SiOZ, 10 pm parti- 
cles) eluted at 2 ml/min with hexane/isopropanol/ace- 
tic acid (92/8/0.01, v/v/v) UV-recording, 280 nm. 
2.3. UV-spectroscopy 
UV-spectroscopy was performed with a Cary 219 
instrument. Spectra were recorded between 320 and 
220 nm, with hexane/isopropanol/acetic acid (92/8/ 
0.01, v/v/v) as solvent. 
2.4. Hydrogenation 
Samples were dissolved in 1 ml methanol and 
cooled to 0°C. PtO, (1 mg) was added, and hydrogen 
bubbled through for 90 s. The catalyst was removed 
by filtration, on a short column of SiOZ, 100 mesh, 
eluted with 10 ml methanol. 
2.5. Gas chromatography-mass spectrometry 
(GC-MS) 
The samples, treated with diazomethane, were con- 
verted to trimethylsilylethers using pyridine, hexa- 
methyldizilazane and trimethylchlorosilane, and an 
LKB-9000 instrument was used for CC-MS analysis. 
The stationary phase of the GCcolumn was SE-30 
(1%) on Supelcoport . The energy of the ionization 
beam was 22.5 eV. 
3. Results 
A preparation of human leukocytes was incubated 
with 15hydroperoxyeicosatetraenoic acid. Four com- 
pounds were isolated and further characterized. These 
new metabolites were formed also in incubations of 
homogenates of leukocytes, with 15-HPETE. Further- 
more, when labeled 15-[ 1 -14C]HPETE was incubated, 
radioactivity was incorporated into the isolated com- 
pounds. 
3 .l . Compounds I and II 
The material in a peak in the straight phase HPLC, 
with a retention time of 37 mm, was collected. The 
UV-spectrum of this fraction showed 3 main bands 
(fig2A) with maxima at 281 nm, 270 nm and 261 nm. 
This is in accordance with the occurrence of 3 con- 
jugated double bonds in the isolated material. 
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Fig.2. (A) UVspectrum of compounds I and II; (B) UV-spec- 
trum of compound III. 
The material was derivatized into the trimethyl- 
silylethers, as in section 2 and subjected to GC-MS. 
Two compounds were separated in the gas chromat- 
ogram. Their C-values were 23.8 and 24.7 (com- 
pounds I and II) (SE-30). The mass spectra of the two 
compounds were practically identical. Fig.3 shows the 
mass spectrum of the compound with C-value 23.8. 
Ions in the mass spectrum were (m/e): 479 @I’-1 5), 
394 (MeaSiOCH(CH)6CH2(CH)2(CH2)3C(OMe)- 
6SiMea, resulting from a rearrangement (see [20]), 
321 (M’-173, loss of Me3SiOCH(CH2)4CH3) and 173 
(Me$&H(CH&CHa, base peak). 
The ion M’-15 indicates a tetra-unsaturated ihy- 
droxy acid, with 20 carbons (A4 = 494). The positions 
of the hydroxyl groups are at C-l 4 and C-l 5, as indi- 
cated by the ions at m/e 32 1 and 173. The ion at 












Fig.3. Upper panel - mass spectrum of compound I. Lower Panel - mass spectrum of compounds I and II after catalytic hydro- 
genation Methyl esters, trimethylsiiyl ethers.) 
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between C-14 and C-20, and the ion at m/e 321 that 
the 4 double bonds are located between C-l and C-14. 
The rearrangement product at m/e 394 can be 
expected for a vicinal 14,15-dihydroxy acid, with 4 
double bonds between C-l and C-14 [20]. The exact 
positions of the double bonds are based on biogenetic 
considerations (see section 4). It was thus assumed that 
the double bonds are located at As, As, Alo and A”. 
When the material in the HPLC-fraction with a 
retention time of 37 min was hydrogenated, prior to 
derivatization into trimethylsilyl ethers and CC-MS, 
a peak with C-value 23.6 (SE-30) was detected in the 
gas chromatogram. The mass spectrum (fig.3) showed 
ions at(m/e): 487(M’-15),471 (M”-31) 451,437,431 
(M’-71, loss of (CH,)&Hs), 402 (Me,Si0CH(CH2)r2- 
C(OMe)&iMe, from a rearrangement (see [20]), 361, 
329 (I&-173, loss of Me,SiOCH(CH,),CH,), 289, and 
173 (Me3Si&H(CH2)&H3, base peak). 
This mass spectrum confirms the concept of a C-20 
carboxylic acid, with two hydroxyl groups (M = 502). 
The positions of the hydroxyl groups (C-l 4 and C-l 5) 
followed from the ions appearing at m/e 329 and 173, 
respectively. The ion at m/e 402, resulting from a 
rearrangement is in accordance with a 14,15-dihy- 
droxy acid [20]. 
Based on these data and the biogenetic considera- 
tions, compounds I and II are proposed to be two iso- 
mers of 14,15dihydroxyeicosa5,8,10,12-tetraenoic 
acid. 
3.2. Compound III 
The retention time in the straight phase HPLC, of 
this compound was 40 mm. The UV-spectrum (fig2B) 
again showed a triplet, with maxima at 280 nm, 
269 nm and 259 nm, suggesting a conjugated triene 
structure also for compound III. 
Following conversion into trimethylsilylethers, 
GC-MS showed a compound with C-value 24.8 
(SE-30). Ions in the mass spectrum of the compound 
(fig A) were at (m/e): 494 @I’), 479 (M’-15), 463 
(M+-31), 423 (M+-7 1, loss of ‘(CH,),CH,), 404 
(M’-90+), loss of trimethylsilanol), 394 (probably 
Me,SiOC(OMe)(CH2),(CH)2CH2CH(OSiMe3)(CH)& 
from a rearrangement, see [20]), 353 (lvl+-141) loss 
of ‘CH,(CH)2(CH2)sCOOMe), 321 (M’-173, loss of 
Me,SiOCH(CH2)&H,), 263 (M’(141 + 90)), 237, 
217 (probably MesSiOCH=CH-CH=OSiMea, from a 
r+earrangement), 199, 19 1 (probably Me,SiOCH= 
OSiMe,, from a rearrangement), 173 (MeaSiOCH- 
(CH&CHa), and 129 (base peak). 
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The ions at m/e 494,479,463 and 404 indicate a 
tetra-unsaturated Czo dihydroxy acid. The position of 
one hydroxyl group (C-l 5) is determined by the ions 
appearing at m/e 423,321 and 173. The other 
hydroxyl group is located at C-8 since there were ions 
appearing at m/e 353 and 263. The positions of the 
double bonds can be assigned to be at A’, A9, Al1 and 
Al3 partly by biogenetic considerations (see section 4). 
This is also supported by the appearance of ions at 
m/e 423 and 173 showing that the molecule is satu- 
rated between C-l 5 and C-20 and ions at m/e 353 and 
263 indicating that one double bond is present 
between C-l and C-8. The conjugated triene (based on 
UV-absorption) is thus localized between C-8 and C-l 5. 
Upon hydrogenation, the C-value of compound III 
shifted to 24.0 (SE-30). The mass spectrum (fig.4) 
was as follows (m/e): 487 (M’-I 5), 431 (M’-7 1, LOSS 
of ‘(CH2)&Hs), 365,359 (M+-143, loss of ‘(CH,),- 
COOMe), 341 (M’(71 + 90) loss of ‘(CH&,CHa + tri- 
methylsilanol), 329 (M’-I 73), loss of Me,SiOCy- 
(CH,)&H,), 269 (M’(l43 t 90)) 245 (MesSiOCH- 
(CH2),COOMe), 2 16 and 173 that is Me aSidCH- 
(CH2)&Hs (base peak). 
The ions at m/e 487 and 43 1 are consistent with a 
Czo dihydroxy acid. The positions of the hydroxyl 
groups at C-8 and C-l 5 were determined by the ions 
(m/e) 359,269,245 and by the ions (m/e) 431,341, 
173, respectively. 
Based on these data, compound III was assigned 
the structure 8J5dihydroxyeicosa5,9,11 ,13-tetra- 
enoic acid. 
3.3. Compound IV 
The retention time on straight phase HPLC of the 
methyl ester of compound IV was 36 min. The 
UV-spectrum was practically the same as for com- 
pound III, indicating 3 conjugated double bonds. 
The trimethylsilylether derivative of the compound 
had an equivalent chain length of 22.3 (SE-30). Ions 
in the mass spectrum were at (m/e): 394 (probably 
MeaSi6C(OMe)(CH2)a(CH),CBzCH(OSiMe3)(CH)~, 
from a rearrangement, see [20]), 263 (M’(141 + 90) 
loss of ‘CH2(CH)2(CH2)sCOOMe plus trimethylsila- 
nol), 243 (Me3Si&HCH2(CH)2(CH2)sCOOMe) and 
173 (MeaSi6CH(CH2)&H,, base peak). 
The mass spectrum was consistent with a Czo tetra- 
unsaturated dihydroxy acid. The ions at m/e 263 and 
243 indicated that one hydroxyl group is located at 
C-8. The ion at m/e 173 located the other hydroxyl 
group to C-l 5. An ion appearing at m/e 394 is in 











Fig.4. Upper panel - mass spectrum of compound III. Lower panel - mass spectrum of compound III after catalytic hydrogena- 
tion. methyl esters, trimethylsilylethers.) 
agreement with a reariangement [20] expected for a 
8 $5 dihydroxy acid. 
The double bonds in compound IV are proposed 
to be at As, A9, A” and Al3 (cf. compound III). 
Furthermore, when compound IV was hydrogen- 
ated, a product with a C-value of 24.0 (SE-30) was 
obtained. The mass spectrum was practically identical 
to that of hydrogenated compound III, described 
above. 
Based on these data, compound IV was assigned to 
be an isomer of 8,15-dihydroxyeicosa-5,9 ,l 1 ,I 3-tetra- 
enoic acid. 
4. Discussion 
In [21] it was shown that leukocytes generate 
1 Shydroxyd ,8,11 ,13~ico~tetraenoi~ acid in addi- 
tion to products oxygenated at C-5. It therefore 
seemed of interest to study the biosynthesis of prod- 
ucts formed by initial oxygenation at C-15. Here, 
1 S-hydroperoxy-5 ,S,l 1 ,13eicosatetraenoic acid 
(1 S-HPETE) was incubated with a preparation of 
human leukocytes. The covalent structures of 4 
metabolites are described. These are 2 isomers of 
14,15-dihydroxyd ,8 ,lO,l ‘Leicosatetraenoic acid and 
2 isomers of 8,15_dihydroxy-5 9,11,13eicosatetra- 
enoic acid. 
The assignment of structures was partly based on 
chromatographic properties in reverse phase and 
straight phase HPLC and in gas chromatography of‘ 
both the parent compounds and their hydrogenated 
derivatives. Furthermore, ultraviolet absorbance and 
mass spectrometry provided detailed information 
about location of double bonds and alcohol groups. 
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The proposed structures are also supported by the 
biogenetic relationship with 1 S-HPETE and the anal- 
ogy with corresponding transformations previously 
described for 5-hydroperoxy6,8,10,14eicosatetra- 
enoic acid. It should be stressed that the stereochem- 
istry of the alcohol groups at C-8 and C-14 have not 
been determined whereas the stereochemistry at C-l 5 
is assumed to be retained. Also, the configurations of 
the double bonds have not been determined. 
The new metabolites of arachidonic acid are pro- 
posed to be formed via an allylic epoxide, viz, 14,15- 
oxido5,8,10,12eicosatetraenoic acid. This epoxide is 
suggested to be protonated and converted to the 
14,l Sdihydroxy or 8,15-dihydroxy derivatives by 
addition of hydroxyl ion at C-l 4 and C-8, respectively. 
This mechanism leads to retention of a conjugated 
triene structure in the dihydroxylated derivatives. 
In view of the structural and biogenetic relation- 
ship with the leukotrienes formed via oxygenation at 
C-5 it is proposed to retain the leukotriene nomencla- 
ture for this group of compounds and to indicate the 
positions of the functional groups. The products 
described are thus 8 ,l 5-LTB4 (two isomers) and 
14,l 5-LTB4 (two isomers) and the proposed precursor 
is 14,l 5-LTA4. Corresponding compounds have also 
been found as metabolites of arachidonic acid [ 181. 
Additional work is in progress to elucidate the 
stereochemistry and possible biological roles of these 
new leukotrienes. 
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